Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
200 participants
INTERVENTIONAL
2020-03-15
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Women Delivered Only by Cesarean Delivery
NCT04080349
Comparison of Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Nulliparous Women
NCT04080336
Vaginal Dinoprostone Administration Prior to an Intrauterine Device Insertion in Multiparous Women.
NCT04046302
Vaginal Dinoprostone Administration Prior to Intrauterine Device Insertion
NCT04079140
Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Women
NCT04505917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vaginal dinoprostone
vaginal dinoprostone 6 mg (two tablets) 3 hours prior to IUD insertion
vaginal dinoprostone
two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
vaginal misoprostol
vaginal misoprostol 400 mcg (two tablets) 3 hours prior to IUD insertion
vaginal misoprostol
two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
placebo
two tablets of placebo similar in shape ,color, odor to the study drugs
placebo
two tablets of placebo given 3 hours prior to IUD insertion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vaginal dinoprostone
two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
vaginal misoprostol
two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
placebo
two tablets of placebo given 3 hours prior to IUD insertion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Samy aly ashour
assistant professor obstetrics and gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AHMED SAMY
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
dinoprostone IUDs
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.